Health Economics

Citations 1-10 of 94 total displayed.

Most recent content (1 Jan 2008):

CLINICAL
The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit

R. M. Ara, J. C. Packham, and K. L. Haywood
Rheumatology 2008; 47: 68-71. [Abstract] [Full Text]  

Past content (since Jan 2001):

CLINICAL
An economic evaluation of three physiotherapy treatments for non-specific neck disorders alongside a randomized trial

M. Lewis, M. James, E. Stokes, J. Hill, J. Sim, E. Hay, and K. Dziedzic
Rheumatology 2007; 46: 1701-1708. [Abstract] [Full Text]  

EDITORIALS
30 million, around 10 000 ... and 18 ... Figuring out the optimal treatment for musculoskeletal conditions in the National Health Service

D. A. Isenberg
Rheumatology 2007; 46: 1219-1220. [Extract] [Full Text]  

BASIC SCIENCE
Interleukin (IL)-23 p19 expression induced by IL-1ß in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-B and AP-1 dependent pathway

F.-L. Liu, C.-H. Chen, S.-J. Chu, J.-H. Chen, J.-H. Lai, H.-K. Sytwu, and D.-M. Chang
Rheumatology 2007; 46: 1266-1273. [Abstract] [Full Text]  

CLINICAL
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout
Rheumatology 2007; 46: 1320-1328. [Abstract] [Full Text]  

CLINICAL
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons
Rheumatology 2007; 46: 1345-1354. [Abstract] [Full Text]  

MATTERS ARISING
Rheumatology nurse specialists—do we need them?

S. M. Oliver
Rheumatology 2007; 46: 1380-1381. [Extract] [Full Text]  

CLINICAL
The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis

E. C. F. Wilson, D. R. W. Jayne, E. Dellow, and R. J. Fordham
Rheumatology 2007; 46: 1096-1101. [Abstract] [Full Text]  

CLINICAL
Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis

C. A. E. Walsh, P. Minnock, C. Slattery, N. Kennedy, F. Pang, D. J. Veale, B. Bresnihan, and O. FitzGerald
Rheumatology 2007; 46: 1148-1152. [Abstract] [Full Text]  

GUIDELINES
Provisional guidelines for applying the Department of Health (England) 18-week-patient pathway to specialist rheumatology care

D. A. Walsh, C. Kelly, A. Bosworth, C. Price, and G. Burbage
Rheumatology 2007; 46: 1200-1206. [Abstract] [Full Text]  

[Next page] Pages: 1 2 3 4 5 6 7 8 9 10